Skip to main content

Table 1 Number, number-needed-to-treat/harm and relative benefit/risk estimate for placebo controlled clinical trials of rofecoxib 50 mg

From: Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review

   Number/total (%) with the outcome with   
Outcome Number of trials Rofecoxib 50 mg Placebo Relative benefit/risk (95% CI) NNT/H (95% CI)
At least 50% pain relief 5 (56) (11) 4.8 (3.3 to 7.2) 2.3 (2.0 to 2.6)
Any adverse event 2 (28) (33) 0.69 (0.44 to 1.08) Not calculated
Nausea 3 (7) (17) 0.48 (0.26 to 0.88) -11 (-6 to -40)
Vomiting 3 (4) (12) 0.36 (0.16 to 0.79) -12 (-7 to -46)